Results 1 to 10 of about 209,193 (336)

Can angiogenesis inhibitor therapy cause changes in imaging features of hepatic hemangioma- Initial study [PDF]

Frontiers in Oncology, 2023
BackgroundTo observe whether anti-angiogenesis therapy can induce changes in size and enhancement characteristics of hepatic hemangioma.Method133 patients with hepatic hemangioma lesions were analyzed and classified into a Bevacizumab group (n=65) and ...
Tang Liu, Wenxue Pan, Shengyuan Lai, Jiawen Luo   +3 more
doaj   +2 more sources

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China [PDF]

Cancer Medicine, 2023
Background Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity.
Guangjian Yang, Yaning Yang, Runze Liu, Weihua Li, Haiyan Xu, Xuezhi Hao, Junling Li, Shuyang Zhang, Fei Xu, Siyu Lei, Yan Wang   +10 more
doaj   +2 more sources

Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma [PDF]

Frontiers in Oncology, 2023
BackgroundLiposarcomas (LPS) are mesenchymal malignancies with four principal subtypes presenting distinct molecular and clinical features. Pleomorphic liposarcoma (PLPS) is one of the rarest and most aggressive subtypes of LPS.
Chenlu Zhang, Wenshuai Liu, Binliang Wang, Na Zhu, Xi Guo, Zhiming Wang, Rongyuan Zhuang, Yang You, Yong Zhang, Hanxing Tong, Weiqi Lu, Yuhong Zhou   +11 more
doaj   +2 more sources

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation [PDF]

Cancer Medicine, 2021
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are currently the primary treatment option for patients with EGFR‐mutant non‐small cell lung cancer (NSCLC).
Hiroaki Kodama, Hirotsugu Kenmotsu, Takanori Kawabata, Akifumi Notsu, Michitoshi Yabe, Naoya Nishioka, Eriko Miyawaki, Taichi Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi   +15 more
doaj   +2 more sources

Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]

Frontiers in Oral Health, 2021
Non peer ...
Abdelhakim Salem, Abdelhakim Salem, Elin Hadler-Olsen, Elin Hadler-Olsen, Ahmed Al-Samadi, Ahmed Al-Samadi   +5 more
doaj   +4 more sources

Endogenous inhibitors of angiogenesis [PDF]

Journal of Cell Science, 2001
In the course of embryonic development, during some normal physiological processes in the adult, such as the female reproductive cycle, and also in a variety of pathologies, including tumour growth, new blood vessels develop from the pre-existing vascular network through endothelial cell sprouting,
Christiana Ruhrberg
openalex   +6 more sources

Therapeutic Response of Soft Tissue Sarcoma With Novel SS18-POU5F1 Fusion: A Case Report

Frontiers in Oncology, 2021
A novel SS18-POU5F1 fusion gene was recently reported in soft tissue sarcoma occurring in three adolescent and young adult patients. Herein, we firstly reported the treatment response of SS18-POU5F1 sarcoma to immune checkpoint inhibitor, angiogenesis ...
Zengjun Liu, Zengjun Liu, Hongtu Yuan, Mingyong Han   +3 more
doaj   +1 more source

An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model

Scientific Reports, 2021
In order to identify more effective therapy for recalcitrant osteosarcoma, we evaluated the efficacy of an mTOR-VEGFR inhibitor combination on tumor growth in a unique osteosarcoma patient-derived orthotopic xenograft (PDOX) mouse model derived from the ...
Hiromichi Oshiro, Yasunori Tome, Kentaro Miyake, Takashi Higuchi, Norihiko Sugisawa, Fuminori Kanaya, Kotaro Nishida, Robert M. Hoffman   +7 more
doaj   +1 more source

Comparative characteristics of the outcomes of the use of multidirectional intravitreal pharmacotherapy in the treatment of diabetic macular edema

Офтальмохирургия, 2021
Purpose. To conduct a comparative analysis of the effectiveness of intravitreal injection of dexamethasone-containing implant and aflibercept in macular edema in patients with diabetes mellitus.Material and methods.
M. M. Bikbov, K. I. Kudoyarova, R. M. Zainullin, T. R. Gilmanshin   +3 more
doaj   +1 more source

A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression

Frontiers in Pharmacology, 2020
Angiogenesis dysregulation contributes to inflammation, infections, immune disorders, and carcinogenesis. Bromodomain-containing protein 4 (BRD4) is an epigenetic reader that recognizes histone proteins and acts as a transcriptional regulator to trigger ...
Zijun Zhou, Xiaoming Li, Zhiqing Liu, Lixun Huang, Yuying Yao, Liuyou Li, Jian Chen, Rongxin Zhang, Rongxin Zhang, Jia Zhou, Lijing Wang, Lijing Wang, Qian-Qian Zhang, Qian-Qian Zhang   +13 more
doaj   +1 more source